Literature DB >> 15809017

Growth hormone responses to varying doses of oral arginine.

Scott R Collier1, Darren P Casey, Jill A Kanaley.   

Abstract

UNLABELLED: Intravenous (IV) arginine invokes an increase in growth hormone (GH) concentrations, however, little is known about the impact of oral arginine ingestion on the GH response.
OBJECTIVE: The purpose of this study was to determine the dose of oral arginine that elicits an optimal GH response and to determine the time course of the response.
DESIGN: Eight healthy males (18-33 years - 24.8+/-1.2 years) were studied on 4 separate occasions. Following an overnight fast at 0700 h, a catheter was placed in a forearm vein. Blood samples were taken every 10 min for 5 h. Thirty minutes after sampling was initiated, the subject ingested a dose of arginine (5, 9 or 13 g) or placebo (randomly assigned).
RESULTS: Mean resting GH values for the placebo, 5, 9 and 13 g day were 0.76, 0.67, 2.0 and 0.79 microg/L (n=6), respectively. Integrated area under the curve was not different with 13 g (197.8+/-65.7 min microg/L), yet it increased with 5 and 9 g compared with the placebo (301.5+/-74.6, 524.28+/-82.9 and 186.04+/-47.8 min microg/L, respectively, P<0.05). Mean peak GH levels were 2.9+/-0.69, 3.9+/-0.85, 6.4+/-1.3 and 4.73+/-1.27 microg/L on each day for the placebo, 5, 9 and 13 g days.
CONCLUSION: In conclusion, 5 and 9 g of oral arginine caused a significant GH response. A 13 g dose of arginine resulted in considerable gastrointestinal distress in most subjects without augmentation in the GH response. The rise in GH concentration started approximately 30 min after ingestion and peaked approximately 60 min post ingestion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15809017     DOI: 10.1016/j.ghir.2004.12.004

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  16 in total

1.  Growth hormone therapy is safe and effective in patients with lysinuric protein intolerance.

Authors:  Harri Niinikoski; Risto Lapatto; Matti Nuutinen; Laura Tanner; Olli Simell; Kirsti Näntö-Salonen
Journal:  JIMD Rep       Date:  2011-06-22

2.  Oral arginine improves linear growth of long bones and the neuroendocrine mechanism.

Authors:  Ming-Yu Jiang; De-Pei Cai
Journal:  Neurosci Bull       Date:  2011-06       Impact factor: 5.203

3.  L-Arginine in pregnant scleroderma patients.

Authors:  Dilia Giuggioli; Michele Colaci; Marco Sebastiani; Clodoveo Ferri
Journal:  Clin Rheumatol       Date:  2010-03-06       Impact factor: 2.980

Review 4.  L-arginine as a nutritional prophylaxis against vascular endothelial dysfunction with aging.

Authors:  Kevin S Heffernan; Christopher A Fahs; Sushant M Ranadive; Eshan A Patvardhan
Journal:  J Cardiovasc Pharmacol Ther       Date:  2010-01-06       Impact factor: 2.457

5.  Dose-dependent relationship between severity of pediatric obesity and blunting of the growth hormone response to exercise.

Authors:  Stacy R Oliver; Jaime S Rosa; Timothy D C Minh; Andria M Pontello; Rebecca L Flores; Marcia Barnett; Pietro R Galassetti
Journal:  J Appl Physiol (1985)       Date:  2009-10-29

6.  The effect of hypocaloric diet enriched in legumes with or without L-arginine and selenium on anthropometric measures in central obese women.

Authors:  Mohammad Alizadeh; Sevana Daneghian; Aida Ghaffari; Alireza Ostadrahimi; Abdolrasoul Safaeiyan; Rassul Estakhri; Bahram Pourghasem Gargari
Journal:  J Res Med Sci       Date:  2010-11       Impact factor: 1.852

7.  Hormonal response to L-arginine supplementation in physically active individuals.

Authors:  Davi Vieira Teixeira da Silva; Carlos Adam Conte-Junior; Vânia Margaret Flosi Paschoalin; Thiago da Silveira Alvares
Journal:  Food Nutr Res       Date:  2014-03-25       Impact factor: 3.894

8.  Effects of β-Hydroxy-β-methylbutyrate Free Acid Ingestion and Resistance Exercise on the Acute Endocrine Response.

Authors:  Jeremy R Townsend; Jay R Hoffman; Adam M Gonzalez; Adam R Jajtner; Carleigh H Boone; Edward H Robinson; Gerald T Mangine; Adam J Wells; Maren S Fragala; David H Fukuda; Jeffrey R Stout
Journal:  Int J Endocrinol       Date:  2015-02-22       Impact factor: 3.257

9.  Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.

Authors:  Susanne M Steggerda; Mark K Bennett; Jason Chen; Ethan Emberley; Tony Huang; Julie R Janes; Weiqun Li; Andrew L MacKinnon; Amani Makkouk; Gisele Marguier; Peter J Murray; Silinda Neou; Alison Pan; Francesco Parlati; Mirna L M Rodriguez; Lee-Ann Van de Velde; Tracy Wang; Melissa Works; Jing Zhang; Winter Zhang; Matthew I Gross
Journal:  J Immunother Cancer       Date:  2017-12-19       Impact factor: 13.751

10.  Conductometric and volumetric studies of atorvastatin in aqueous solution of arginine from 298.15 to 313.15 K.

Authors:  M M R Meor Mohd Affandi; Minaketan Tripathy; A B A Majeed
Journal:  J Adv Pharm Technol Res       Date:  2016 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.